Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.

Lo Re, Vincent; Haynes, Kevin; Ming, Eileen E; Wood Ives, Jennifer; Horne, Laura N; Fortier, Kimberly; Carbonari, Dena M; Hennessy, Sean; Cardillo, Serena; Reese, Peter P; +12 more... Reddy, K Rajender; Margolis, David; Apter, Andrea; Kimmel, Stephen E; Roy, Jason; Freeman, Cristin P; Razzaghi, Hanieh; Holick, Crystal N; Esposito, Daina B; Van Staa, Tjeerd-Pieter; Bhullar, Harshvinder; Strom, Brian L; (2012) Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiology and drug safety, 21 (11). pp. 1202-1215. ISSN 1053-8569 DOI: https://doi.org/10.1002/pds.3318

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1002/pds.3318

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar